NOX-A12 - TME Pharma
NOX-A12 (olaptesed pegol) is an intravenously administered, PEGylated L-stereoisomer RNA aptamer that targets CXCL12 (C-X-C Chemokine Ligand 12), a key chemokine (signaling) protein. Chemokines can be thought of as road signs in the body that direct movement of cells that encounter them.
新药巡礼：核酸“抗体”曙光已现，NOX-A12发力肿瘤治疗
2021年12月13日 · NOX-A12（olaptesed pegol）是由NOXXON Pharma开发的一款靶向基质细胞衍生因子-1（SDF-1，又称趋化因子CXCL12）的聚乙二醇化的核酸适配体药物。 该药物是利用NOXXON的专有技术Spiegelmers生产的化合物（L-立体异构体）。
L-RNA aptamer-based CXCL12 inhibition combined with ... - Nature
2024年5月28日 · Targeting CXCL12 with the pegylated L-RNA aptamer olaptesed pegol (NOX-A12) was highly effective in an autochthonous rat brain tumor model mimicking a highly treatment-refractory GBM 32. In this...
胶质母细胞瘤一线治疗最新动态：NOX-A12联合放疗提高临床获 …
NOX-A12(olaptesed pegol)是一种静脉注射的、PEG化的L-stereoisomer RNA适配体，针对CXCL12，一种关键的化学因子(信号传导)蛋白。 2014年， 美国食品和药物管理局 授予NOX-A12孤儿药称号，与放射治疗联合用于胶质母细胞瘤患者。
Olaptesed pegol (NOX-A12) with bendamustine and rituximab: a ... - PubMed
Olaptesed pegol (NOX-A12) is a pegylated structured L-oligoribonucleotide that binds and neutralizes CXCL12, a chemokine tightly regulating the life cycle of chronic lymphocytic leukemia cells. The resulting inhibition of CXCR4 and CXCR7 signaling reduces the protective activity of the bone marrow a …
TME Pharma Provides Results of Fifth Exercise of Warrants Z
2 天之前 · TME Pharma has delivered top-line data from the NOX-A12 three dose-escalation cohorts combined with radiotherapy of the GLORIA clinical trial, observing consistent tumor reductions and objective ...
胶质母细胞瘤治疗最新进展2023：NOX-A12联合疗法显示持久临 …
2023年11月2日 · NOX-A12(olaptesed pegol)是针对关键的趋化因子蛋白CXCL12而开发的。 在癌症中，这种趋化因子蛋白是肿瘤细胞和环境之间的沟通桥梁，已知它鼓励肿瘤增殖，形成新的血管和转移，并减少细胞死亡。
NOX-A12 in newly diagnosed brain cancer patients who will not benefit clinically from standard chemotherapy. TME Pharma has delivered top-line data from the NOX-A12 three dose-escalation cohorts combined with radiotherapy of the GLORIA clinical trial, observing consistent tumor reductions and objective tumor responses.
TME Pharma Provides Results of Fifth Exercise of Warrants Z
2 天之前 · GLORIA (NCT04121455) is TME Pharma’s dose-escalation, Phase 1/2 study of NOX-A12 in combination with radiotherapy in first-line partially resected or unresected glioblastoma (brain cancer ...
Spiegelmer Nox-A12，一种新型 SDF-1 (CXCL12) 抑制剂，及其对 …
摘要 3878 NOX-A12 是一种聚乙二醇化镜像寡核苷酸（一种所谓的 Spiegelmer），它以高亲和力（约 200 pM）结合趋化因子 SDF-1/CXCL12，从而有效抑制其活性。CXCL12 由骨髓基质细胞 (BMSC) 组成型分泌，作为正常和恶性造血细胞进入骨髓的归巢因子。它通过在循环 CLL 细胞上高水平表达的 CXCR4 受体诱导白血病细胞 ...